News

The phase 3 Aspire study of apazunersen did not meet its primary cognition end point or key secondary end point in Angelman syndrome.

A recently published multiple sclerosis study suggests disease-modifying therapy use may be associated with higher rates of human papillomavirus positivity, cervical abnormalities, and other gynecologic complications.

Thayne Munce, PhD, discusses the challenges and unanswered questions shaping CTE research, as well as the implications of findings from former NFL players for athletes competing today.

uniQure submitted a BLA to FDA and an MAA to the UK's MHRA for ifezuntirgene inilparvovec, based on 3-year phase 1/2 data showing slowed Huntington disease progression.

The updated guideline offers evidence-graded recommendations on when to start migraine prevention, which medications to choose, and how to manage special populations.

The neurologist at the UCSF Edward and Pearl Fein Memory and Aging Center discusses how the first platform trial in progressive supranuclear palsy could accelerate the evaluation of potential disease-modifying therapies. [WATCH TIME: 4 minutes]

The European Commission approved modified-release carbidopa/levodopa capsules, already available in the US as Crexont, for adults with moderate to severe motor fluctuations.

The randomized NATURE trial, presented as late-breaking science at ESC Congress 2026, showed that enVast-assisted thrombectomy reduced infarct size versus standard PCI in STEMI with large thrombus burden.

The chair of the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery discussed the major themes, clinical takeaways, and unanswered questions from the first update to the guideline in a decade.

An analysis of more than 311,000 UK Biobank participants identified 13 pairs and 14 triplets of risk factors with significant additive interactions for late-onset Parkinson disease, with several potentially modifiable factors emerging as targets for prevention.

Lucy Morse, MD, a movement disorders specialist at Northwestern Medicine, discussed the push toward a biological definition for Parkinson disease, newly approved therapies, and why she believes referrals shouldn't wait.

Findings showed that remibrutinib outperformed teriflunomide in the REMODEL-1 and REMODEL-2 phase 3 trials among adults with relapsing MS, lowering relapse rates and MRI lesions with a favorable safety profile.

Hannah Kopinsky, MD, an MS specialist at Northwestern Medicine, discussed recent updates to multiple sclerosis diagnostic criteria, the shift toward early high-efficacy treatment, and the unmet needs that remain in progressive MS.

A case report documented MOG-IgG antibodies in a mother's breast milk following severe MOGAD, though her breastfed infant's serum tested negative.

Phase 1b/2 findings showed that the investigational anti-amyloid monoclonal antibody ABBV-916 produced dose-dependent reductions in brain amyloid in adults with early Alzheimer disease, although development of the agent was discontinued before dose expansion because of sponsor business considerations.

In recognition of SMA Awareness Month, NeurologyLive® spoke with neuromuscular experts about how multidisciplinary care is built, where coordination breaks down, and what changes as patients live longer.

A phase 1 feasibility trial found that placing GammaTile radiation therapy directly into the surgical cavity during glioblastoma resection sharply reduced rapid early tumor regrowth compared with historical rates, setting up a phase 3 randomized trial.

In recognition of SMA Awareness Month, NeurologyLive® spoke with neuromuscular experts about how multidisciplinary care is built, where coordination breaks down, and what changes as patients live longer.

Here's some of what is coming soon to NeurologyLive® this week.

Catch up on any of the neurology headlines you may have missed from last week, compiled into 1 place by the NeurologyLive® team.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is pediatric epilepsy care!

In honor of SMA Awareness Month, held annually throughout August, get caught up on the latest news in spinal muscular atrophy from 2026, 5 headlines compiled in one place by the NeurologyLive® team.

Neurology News Network for the week ending August 29th, 2026. [WATCH TIME: 5 minutes]

Findings from a phase 1 study showed that bilateral putaminal delivery of AAV2-GDNF using convection-enhanced delivery was well tolerated over 5 years, although exploratory clinical measures did not demonstrate significant improvements from baseline.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 28, 2026.

The vice president of Neuroscience and Vaccines at Takeda discusses the clinical significance of oveporexton's FDA approval and how restoring orexin signaling may reshape treatment expectations in narcolepsy type 1.

In recognition of SMA Awareness Month, held annually throughout August, NeurologyLive® reviews the investigational agents currently moving through clinical development for spinal muscular atrophy.

Mitzi Joi Williams, MD, is joined by Jakai McEwen, DO, and Jacqueline Rosenthal, MD, to discuss the medical uses of botulinum toxin across neurologic conditions, including chronic migraine and spasticity, as well as treatment expectations, shared decision-making, and common misconceptions surrounding Botox.